Global Contraceptive Drugs Market is Expected to Reach Till $ 22.15 Billion By 2023

Pune, India, July 2017 /MRFR Press Release/- Market Research Future published a half-cooked research report on global contraceptive drugs market.

Key Highlights on Contraceptive Drugs Market 

Contraceptive drugs has got a special attention from 20th century. These are the products that helps to avoid unwanted birth. These products help in preventing the pregnancy by blocking or altering the process of ovulation. The major driving factor for the growth of global contraceptive drugs market is increasing need to control the population. Beside this economic advances, increasing awareness different government initiatives are also responsible for the growth of the global contraceptive drugs market. On other hand side effects of the contraceptives, many religious and cultural opposition may restrain the growth of the market. The global market for contraceptive drugs is expected to reach $ 22.15 billion by the end of the 2023 form $ 13.9 billion in 2016, at a CAGR of 6.5%.

Segmentation: Global contraceptive drugs market is segmented on two category by type and by end user. On the basis of type they are oral contraceptive, injectable and other. Oral contraceptives are further sub segmented into combined oral contraceptive pills and progestogen- only pills. On the basis of end user they are segmented as hospitals, clinics and others. 

Competitive Analysis

The major key player for the global contraceptive drugs market are Merck & Co., Inc (US), Pfizer Inc (US), Teva Pharmaceutical Industries Ltd. (Israel), Bayer AG (Germany), Allergan plc. (Ireland), Janssen Global Services llc. (US), Mankind Pharma Ltd. (India), Piramal Enterprises Ltd (India), Reckitt Benckiser Plc (UK), Church & Dwight (US), The Female Health Company (US), Mayer Laboratories (US), Cooper Surgical (US).Global contraceptive market is contributed by many of the small and large companies. Major companies are investing in R&D so as to introduce more innovative and efficient contraceptives drugs as they are under constant pressure to launch new and technologically advanced products.  Companies are launcing new product so as to withstand the competition and increase the market.Pfizer Inc one of the leading research and pharmaceutical company headquartered in US. In 2015, they has introduced SAYANA, first injectable contraceptive in UK which can be self-administered. Loette, Premarin and Ovral are some of the major products of Pfizer.Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Israel. In 2015, company has launched Beyaz which is a generic contraceptive drug. It is one of the most successful product of the company and in 2016 it has annual sales of approximately $133 million in the US. Recently, in March 2017 Company has announce to launch a new product Minastrin.Merck & Co., Inc is one of the largest pharmaceutical companies in the world headquartered in US. Cyclessa, Desogen and Dificid are some of the major products of the company.Bayer AG is a multinational chemical, pharmaceutical company headquartered in Germany. Company has developed a new class of birth control pill QLAIRA. This drug has shown a well-tolerated and high satisfaction rate in studies.Allergan plc is the multinational company headquartered in Ireland. This company produces branded and generic drugs and performs pharmaceutical research and development. In 2016, company has announce to launch TAYTULLA, first and only oral contraceptive in a softgel capsule.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Contraceptive Drugs Market Research Report